SYDNEY, Australia & AUCKLAND, New Zealand & BOULDER, Colo.--(BUSINESS WIRE)--Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today updated shareholders at their Annual General Meeting in Adelaide, Australia on the Phase I/IIa clinical trial of DiabeCell®, LCT’s lead product candidate for the treatment of insulin dependent (Type 1) diabetes.
